Skip to main content

Cytomegalovirus

3
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

RNA Therapeutic
1100%
+ 3 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Kamada
KamadaIsrael - Negev
1 program
1
Cytomegalovirus Immune Globulin IntravenousPhase 41 trial
Active Trials
NCT06958796Recruiting80Est. May 2028
BioTherapeutics Inc
BioTherapeutics IncVA - Blacksburg
1 program
1
CMV-pp65 CTLsPhase 2
Atara Biotherapeutics
Atara BiotherapeuticsCA - Thousand Oaks
1 program
1
CMV-pp65 CTLsPhase 21 trial
Active Trials
NCT01646645Completed58Est. Dec 2019
Moderna
ModernaCAMBRIDGE, MA
1 program
mRNA-1647PHASE_1_2RNA Therapeutic1 trial
Active Trials
NCT05575492Active Not Recruiting873Est. Jan 2027

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
KamadaCytomegalovirus Immune Globulin Intravenous
Atara BiotherapeuticsCMV-pp65 CTLs
ModernamRNA-1647

Clinical Trials (3)

Total enrollment: 1,011 patients across 3 trials

NCT06958796KamadaCytomegalovirus Immune Globulin Intravenous

Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)

Start: Nov 2025Est. completion: May 202880 patients
Phase 4Recruiting

Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation

Start: Jul 2012Est. completion: Dec 201958 patients
Phase 2Completed

A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age

Start: Nov 2022Est. completion: Jan 2027873 patients
Phase 1/2Active Not Recruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 1,011 patients
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.